Eisana Health

Preventing nerve damage from chemotherapy
Houston, The Woodlands

About Eisana Health

Eisana Health is a development stage medical device company, based in The Woodlands, Texas. We are focused on preventing devastating side effects from cancer treatment. Our first product is a cooling system for hands and feet, specifically tailored to the unique needs of cancer patients, to prevent painful and incurable nerve damage caused from many common chemo drugs.

Tagged with

Team

Problem statement

Many common chemotherapy drugs make their way in the blood to fingers and toes and destroy sensitive nerve endings. This chemotherapy-induced peripheral neuropathy (CIPN) is horrible on several levels:
• Common, painful, and debilitating;
• Not curable;
• Dramatically decreases quality of life for survivors;
• Payors are spending an average of $17k, per year, per patient, just trying to deal with symptoms;
• Oncologists struggle with two bad choices when it occurs in the middle of several rounds of chemo:
keep going and cause a permanent disability or stop treatment and the patient dies.

A poster was presented at last year's American Society of Clinical Oncologists (ASCO) conference showing a 55% reduction in nerve damage with cooling, concluding that all patients receiving neurotoxic chemo drugs should be encouraged to cool their hands and feet on the day of chemo.

Problem is, there's no easy and safe way to do it. Patients are struggling with ice cold solutions, designed for injury or rehabilitation: 20 minutes on, 20 minutes off. Cancer patients need less cold, uninterrupted, for several hours while the drug is at a high concentration in the blood. Eisana Health is the first company to design cooling gloves that allow a patient to use their hands (phone, eat, read, etc) and cooling booties that allow a patient to use their feet (walk).

Traction information

Closed a $900,000 pre-seed, angel round.

Filed two patents through the PCT, entered 8 countries and the EU.

Developed alpha prototype.

Received $400k Phase 1 SBIR Contract from the National Cancer Institute.

Will complete formative human factors study 7/2024.

Updates

Bella Taylor has visited this profile using a private link.
Added about 2 months ago
Profile created.
Added about 2 months ago

Funding

Currently raising capital

$525,000
committed
$1,500,000
round goal
Total raised to date:$1,500,000

Network

Pitch is a Capital Factory product. © Capital Factory 2024. Privacy policy.